Risks to the Stable Supply and Competitiveness of Generic Drugs
First written in FY2016-Q3. 10 of 11 entries say "Restated". Latest entry: FY2019-Q3.
1 other company's latest entry also says "Restated".
- FY2019-Q3RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
The company continues to recognize the need to address stable supply and further drug price reductions despite expectations for generic market expansion. - FY2019-Q2RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
The company continues to recognize the need to address stable supply and further drug price reductions despite expectations for generic market expansion. - FY2019-Q1RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
The company continues to document expectations for generic market expansion and measures to address stable supply and further drug price reductions. - FY2018-Q3RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
The company continues to document expectations for generic market expansion and measures to address stable supply and further drug price reductions. - FY2018-Q2RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
As before, the company continues to document expectations for generic market expansion and measures to address stable supply and further drug price reductions. - FY2018-Q1RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
The company continues to document expectations for higher generic market volumes and measures to address stable supply and further drug price reductions. - FY2017RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
Despite generic market expansion, the company continues to identify stable supply and further drug price reductions as challenges and risks. - FY2017-Q3RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
The company continues to document expectations for generic market expansion and measures to address stable supply and further drug price reductions. - FY2017-Q2RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
The company continues to document expectations for generic market expansion and measures to address stable supply and further drug price reductions. - FY2017-Q1RestatedAnnual report
「The volume of generic pharmaceuticals supplied is expected to increase further as an important measure to contain national healthcare spending. At the same time, measures to ensure stable supply and further drug price reductions are anticipated.」
The company continues to document expectations for generic market expansion and measures to address stable supply and further drug price reductions. - FY2016-Q3First statedAnnual report
「The generic pharmaceuticals market has continued to expand. At the same time, measures to ensure stable supply and further cuts in drug prices are expected.」
Despite market expansion, stable supply and further drug price declines are identified as challenges and risks.